Skip to content
Screener

Novavax NVAX Europe — Revenue from Contract with Customer, Excluding Assessed Tax

Other geography segments

Rest of North America
$575.67M+12,802%
Rest of the world
$17.14M-54.2%

Similar metrics at other companies

Keysight Technologies logo
KEYSEurope — Revenue from Contract with Customer, Excluding Assessed Tax
$328M+47.1%
Ameresco logo
AMRCEurope — Revenue from Contract with Customer, Excluding Assessed Tax
$127.43M+31.8%
AtriCure logo
ATRCEurope — Revenue from Contract with Customer, Excluding Assessed Tax
$17.21M+6.7%
Mettler-Toledo International, Inc. logo
MTDEurope — Revenue from Contract with Customer, Excluding Assessed Tax
$278.69M+12.4%
AptarGroup logo
ATREurope — Revenue from Contract with Customer, Excluding Assessed Tax
$465.64M+5.2%
Jazz Pharmaceuticals logo
JAZZEurope — Revenue from Contract with Customer, Excluding Assessed Tax
$92.4M+10.5%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2025Six Months Ended June 30, 2024
United States$38,437$198,183$134,530$237,593
Canada575,670
Europe1,1183,62721,26411,712
Rest of the world17,14337,43040,41880,920
Total revenue$56,698$239,240$196,212$905,895

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's europe — revenue from contract with customer, excluding assessed tax?
Novavax (NVAX) reported europe — revenue from contract with customer, excluding assessed tax of $1.12M in Q2 2026.
How has Novavax's europe — revenue from contract with customer, excluding assessed tax changed year-over-year?
Novavax's europe — revenue from contract with customer, excluding assessed tax decreased by 69.2% year-over-year, from $3.63M to $1.12M.
What is the long-term trend for Novavax's europe — revenue from contract with customer, excluding assessed tax?
Over 3 years (2022 to 2025), Novavax's europe — revenue from contract with customer, excluding assessed tax has grown at a -73.3% compound annual growth rate (CAGR), from $826.83M to $15.74M.
What does europe — revenue from contract with customer, excluding assessed tax mean?
This metric represents the total revenue recognized from contracts with customers within the European geographic segment, excluding any assessed taxes such as sales or value-added taxes. It serves as a primary indicator of the company's commercial performance and market penetration within the European region. Monitoring this figure helps investors assess the demand for the company's products and the effectiveness of its regional sales strategy.

Ask your AI about Novavax's europe — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude